Strain-specific neutralization of human cytomegalovirus isolates by human sera

Journal of Virology

Volumn 73, Issue 2, 1999, Pages 878-886

  Klein, M ^a   Schoppel, K ^a   Amvrossiadis, N ^a   Mach, M ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS VACCINE; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; NONHUMAN; PRIORITY JOURNAL; VIRUS ENVELOPE; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS STRAIN;

EID: 0032933835     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.73.2.878-886.1999     Document Type: Article

References (50)

1. Adler, S. P. 1996. Current prospects for immunization against cytomegaloviral disease. Infect. Agents Dis. 5:29-35.
2. Adler, S. P., S. E. Starr, S. A. Plotkin, S. H. Hempfling, J. Buis, M. L. Manning, and A. M. Best. 1995. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J. Infect. Dis. 171:26-32.
3. Almeida, J., D. Lang, and P. Talbot. 1978. Herpesvirus morphology: visualization of a structural subunit. Intervirology 10:318-320.
4. Andreoni, M., M. Faircloth, L. Vugler, and W. J. Britt. 1989. A rapid microneutralization assay for the measurement of neutralizing antibody reactive with human cytomegalovirus. J. Virol. Methods 23:157-167.
5. Andrews, C. H., and W. J. Elford. 1933. Observations on anti-phage sera. 1: "The Percentage Law." Br. J. Exp. Pathol. 14:367-375.
6. Baboonian, C., K. Blake, J. C. Booth, and C. N. Wiblin. 1989. Complement-independent neutralising monoclonal antibody with differential reactivity for strains of human cytomegalovirus. J. Med. Virol. 29:139-145.
7. Bachmann, M. F., U. Kalinke, A. Althage, G. Freer, C. Burkhart, H.-P. Roost, M. Aguet, H. Hengartner, and R. M. Zinkernagel. 1997. The role of antibody concentration and avidity in antiviral protection. Science 276:2024-2027.
8. Brioen, P., and A. Boeye. 1985. Poliovirus neutralization and the percentage law. Brief report. Arch. Virol. 83:105-111.
9. Britt, W. J., and D. Auger. 1985. Identification of a 65,000-dalton virion envelope protein of human cytomegalovirus. Virus Res. 4:31-36.
10. Britt, W. J., and M. Mach. 1996. Human cytomegalovirus glycoproteins. Intervirology 39:401-412.
11. Britt, W. J., L. Vugler, E. J. Butfiloski, and E. B. Stephens. 1990. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-rccombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J. Virol. 64:1079-1085.
12. Chandler, S. H., and J. K. McDougall. 1986. Comparison of restriction site polymorphisms among clinical isolates and laboratory strains of human cytomegalovirus. J. Gen. Virol. 67:2179-2192.
13. Chehimi, J., J. Peppard, and D. Emanuel. 1987. Selection of an intravenous immune globulin for the immunoprophylaxis of cytomegalovirus infections: an in vitro comparison of currently available and previously effective immune globulins. Bone Marrow Transplant. 2:395-402.
14. Chou, S. 1992. Molecular epidemiology of envelope glycoprotein H of human cytomegalovirus. J. Infect. Dis. 166:604-607.
15. Chou, S. W. 1989. Neutralizing antibody responses to reinfecting strains of cytomegalovirus in transplant recipients. J. Infect. Dis. 160:16-21.
16. Chou, S. W., and K. M. Dennison. 1991. Analysis of interstrain variation in cytomegalovirus glycoprotein B sequences encoding neutralization-related epitopes. J. Infect. Dis. 163:1229-1234.
17. Ehrlich, P. H., K. E. Harfeldt, J. C. Justice, Z. A. Moustafa, and L. Ostberg. 1987. Rhesus monkey responses to multiple injections of human monoclonal antibodies. Hybridoma 6:151-160.
18. Farrell, H. E., and G. R. Shellam. 1991. Protection against murine cytomegalovirus infection by passive transfer of neutralizing and non-neutralizing monoclonal antibodies. J. Gen. Virol. 72:149-156.
19. Fowler, K. B., S. Stagno, R. F. Pass, W. J. Britt, T. J. Boll, and C. A. Alford. 1992. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N. Engl. J. Med. 326:663-667.
20. Fries, B. C., S. Chou, M. Boeckh, and B. Torok Storb. 1994. Frequency distribution of cytomegalovirus envelope glycoprotein genotypes in bone marrow transplant recipients. J. Infect. Dis. 169:769-774.
21. Grillner, L., and K. Strangert, 1988. A prospective molecular epidemiological study of cytomegalovirus infections in two day care centers in Sweden: no evidence for horizontal transmission within the centers. J. Infect. Dis. 157: 1080-1083.
22. Grundy, J. E., S. F. Lui, M. Super, N. J. Berry, P. Sweny, O. N. Fernando, J. Moorhead, and P. D. Griffiths. 1988. Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus. Lancet 2:132-135.
23. Ho, M. 1993. Cytomegalovirus: biology and infection. Plenum Medical Book, New York, N.Y.
24. Irmiere, A., and W. Gibson. 1983. Isolation and characterization of a non-infectious virion-like particle released from cells infected with human strains of cytomegalovirus. Virology 130:118-133.
25. Jonjic, S., I. Pavic, B. Polic, I. Crnkovic, P. Lucin, and U. H. Koszinowski. 1994. Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. J. Exp. Med. 179: 1713-1717.
26. Kilpatrick, B. A., E.-S. Huang, and J. S. Pagano. 1976. Analysis of cytomegalovirus genomes with restriction endonucleases HinD III and EcoR-1. J. Virol. 18:1095-1105.
27. Klages, S., B. Ruger, and G. Jahn. 1989. Multiplicity-dependent expression of the predominant phosphoprotein pp65 of human cytamegalovirus. Virus Res. 12:159-168.
28. Klein, M. Unpublished data.
29. Lehner, R., T. Stamminger, and M. Mach. 1991. Comparative sequence analysis of human cytomegalovirus strains. J. Clin. Microbiol. 29:2494-2502.
30. Marshall, G. S., G. P. Rabalais, G. G. Stout, and S. L. Waldeyer. 1992. Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity. J. Infect. Dis. 165:381-384.
31. Masuho, Y., Y. Matsumoto, T. Sugano, S. Fujinaga, and Y. Minamishima. 1987. Human monoclonal antibodies neutralizing human cytomegalovirus. J. Gen. Virol. 68:1457-1461.
32. Masuho, Y., Y. Matsumoto, T. Tomiyama, T. Sugano, and S. Ono. 1990. Characterization of human anti-cytomegalovirus monoclonal antibody as biologies. Dev. Biol. Stand. 71:127-136.
33. Meyer, H., V. A. Sundqvist, L. Pereira, and M. Mach. 1992. Glycoprotein gp116 of human cytomegalovirus contains epitopes for strain-common and strain-specific antibodies. J. Gen. Virol. 73:2375-2383.
34. Plotkin, S. A., S. E. Starr, H. M. Friedman, E. Gonczol, and K. Brayman. 1990. Vaccines for the prevention of human cytomegalovirus infection. Rev. Infect. Dis. 12(Suppl. 7):827-838.
35. Rapp, M., M. Messerle, B. Buhler, M. Tannheimer, G. M. Keil, and U. H. Koszinowski. 1992. Identification of the murine cytomegalovirus glycoprotein B gene and its expression by recombinant vaccinia virus. J. Virol. 66: 4399-4406.
36. Rasmussen, L. E., R. M. Nelson, D. C. Kelsall, and T. C. Merigan. 1984. Murine monoclonal antibody to a single protein neutralizes the infectivity of human cytomegalovirus. Proc. Natl. Acad. Sci. USA 81:876-880.
37. Reddehase, M. J., M. Balthesen, M. Rapp, S. Jonjic, I. Pavic, and U. H. Koszinowski. 1994. The conditions of primary infection define the load of latent viral genome in organs and the risk of recurrent cytomegalovirus disease. J. Exp. Med. 179:185-193.
38. Roizman, B. 1993. The family Herpesviridae: a brief introduction, p. 1-9. In B. Roizman, R. J. Whitley, and C. Lopez (ed.), The human herpesviruses. Raven Press, New York, N.Y.
39. Schmitz, H., and S. Essuman. 1986. Comparison of the neutralizing and ELISA antibody titres to human cytomegalovirus (HCMV) in human sera and in gamma globulin preparations. J. Med. Virol. 20:177-182.
40. Schoppel, K., B. Kropff, C. Schmidt, and M. Mach. 1997. The humoral immune response against the human cytomegalovirus is characterized by a delayed synthesis of glycoprotein specific antibodies. J. Infect. Dis. 175:533-544.
41. Shepp, D. H., M. E. Match, A. B. Ashraf, S. M. Lipson, C. Millan, and R. Pergolizzi. 1996. Cytomegalovirus glycoprotein B groups associated with retinitis in AIDS. J. Infect. Dis. 174:184-187.
42. Snydman, D. R. 1991. Prevention of cytomegalovirus-associated diseases with immunoglobulin. Transplant. Proc. 23:131-135.
43. Spear, G. T., N. S. Lurain, C. J. Parker, M. Ghassemi, G. H. Payne, and M. Saifuddin. 1995. Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses. Human T cell leukemia/lymphoma virus type 1 (HTLV-I) and human cytomegalovirus (HCMV). J. Immunol. 155:4376-4381.
44. Spiller, O. B., B. P. Morgan, F. Tufaro, and D. V. Devine. 1996. Altered expression of host-encoded complement regulators on human cytomegalovirus-infected cells. Eur. J. Immunol. 26:1532-1538.
45. Stagno, S., R. F. Pass, M. E. Dworsky, R. E. Henderson, E. G. Moore, P. D. Walton, and C. A. Alford. 1982. Congenital cytomegalovirus infection: the relative importance of primary and recurrent maternal infection. N. Engl. J. Med. 306:945-949.
46. Urban, M., W. Britt, and M. Mach. 1992. The dominant linear neutralizing antibody-binding site of glycoprotein gp86 of human cytomegalovirus is strain specific. J. Virol. 66:1303-1311.
47. Urban, M., M. Klein, W. J. Britt, E. Hassfurther, and M. Mach. 1996. Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response. J. Gen. Virol. 77:1537-1547.
48. Waner, J. L., and T. H. Weller. 1978. Analysis of antigenic diversity among human cytomegaloviruses by kinetic neutralization tests with high-titered rabbit antisera. Infect. Immun. 21:151-157.
49. Zablotney, S. L., B. B. Wentworth, and E. R. Alexander. 1978. Antigenic relatedness of 17 strains of human cytomegalovirus. Am. J. Epidemiol. 107: 336-343.
50. Zaia, J. A. 1993. Prevention and treatment of cytomegalovirus pneumonia in transplant recipients. Clin. Infect. Dis. 17(Suppl. 2):392-399.